A citation-based method for searching scientific literature

Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
Times Cited: 179







List of co-cited articles
1348 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Sarah J Hill, Brennan Decker, Emma A Roberts, Neil S Horowitz, Michael G Muto, Michael J Worley, Colleen M Feltmate, Marisa R Nucci, Elizabeth M Swisher, Huy Nguyen,[...]. Cancer Discov 2018
200
8

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
970
7

Coupling of Homologous Recombination and the Checkpoint by ATR.
Rémi Buisson, Joshi Niraj, Amélie Rodrigue, Chu Kwen Ho, Johannes Kreuzer, Tzeh Keong Foo, Emilie J-L Hardy, Graham Dellaire, Wilhelm Haas, Bing Xia,[...]. Mol Cell 2017
99
7

An intrinsic S/G2 checkpoint enforced by ATR.
Joshua C Saldivar, Stephan Hamperl, Michael J Bocek, Mingyu Chung, Thomas E Bass, Fernanda Cisneros-Soberanis, Kumiko Samejima, Linfeng Xie, James R Paulson, William C Earnshaw,[...]. Science 2018
144
7

ATM Mutations in Cancer: Therapeutic Implications.
Michael Choi, Thomas Kipps, Razelle Kurzrock. Mol Cancer Ther 2016
255
7

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li,[...]. Sci Transl Med 2017
136
7

The DNA-damage response in human biology and disease.
Stephen P Jackson, Jiri Bartek. Nature 2009
7

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
U A Matulonis, G M Wulf, W T Barry, M Birrer, S N Westin, S Farooq, K M Bell-McGuinn, E Obermayer, C Whalen, T Spagnoletti,[...]. Ann Oncol 2017
140
7

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
249
7

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Frank P Vendetti, Pooja Karukonda, David A Clump, Troy Teo, Ronald Lalonde, Katriana Nugent, Matthew Ballew, Brian F Kiesel, Jan H Beumer, Saumendra N Sarkar,[...]. J Clin Invest 2018
99
7

The DNA damage response: making it safe to play with knives.
Alberto Ciccia, Stephen J Elledge. Mol Cell 2010
7

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Aparajitha Vaidyanathan, Lynne Sawers, Anne-Louise Gannon, Probir Chakravarty, Alison L Scott, Susan E Bray, Michelle J Ferguson, Gillian Smith. Br J Cancer 2016
176
7

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Rachna T Shroff, Andrew Hendifar, Robert R McWilliams, Ravit Geva, Ron Epelbaum, Lindsey Rolfe, Sandra Goble, Kevin K Lin, Andrew V Biankin, Heidi Giordano,[...]. JCO Precis Oncol 2018
119
7

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu,[...]. Cancer Discov 2017
264
7

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate.
Cecilia E Ström, Fredrik Johansson, Mathias Uhlén, Cristina Al-Khalili Szigyarto, Klaus Erixon, Thomas Helleday. Nucleic Acids Res 2011
206
7

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
7

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
375
7

Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
Arnab Ray Chaudhuri, Yoshitami Hashimoto, Raquel Herrador, Kai J Neelsen, Daniele Fachinetti, Rodrigo Bermejo, Andrea Cocito, Vincenzo Costanzo, Massimo Lopes. Nat Struct Mol Biol 2012
328
7

Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Ross A Stewart, Patrick G Pilié, Timothy A Yap. Cancer Res 2018
118
7

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Lin Mei, Junran Zhang, Kai He, Jingsong Zhang. J Hematol Oncol 2019
65
10

MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
Delphine Lemaçon, Jessica Jackson, Annabel Quinet, Joshua R Brickner, Shan Li, Stephanie Yazinski, Zhongsheng You, Grzegorz Ira, Lee Zou, Nima Mosammaparast,[...]. Nat Commun 2017
209
7

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
J F Liu, W T Barry, M Birrer, J-M Lee, R J Buckanovich, G F Fleming, B J Rimel, M K Buss, S R Nattam, J Hurteau,[...]. Ann Oncol 2019
84
8

Biomarker-Guided Development of DNA Repair Inhibitors.
James M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, Alan D D'Andrea. Mol Cell 2020
98
7

Repair Pathway Choices and Consequences at the Double-Strand Break.
Raphael Ceccaldi, Beatrice Rondinelli, Alan D D'Andrea. Trends Cell Biol 2016
806
7

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R E Miller, A Leary, C L Scott, V Serra, C J Lord, D Bowtell, D K Chang, D W Garsed, J Jonkers, J A Ledermann,[...]. Ann Oncol 2020
116
7

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Amit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I Weberpals, Robert M Wenham, Naomi Laing,[...]. Clin Cancer Res 2020
49
14

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
William P Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael Bookman, Monica Brown Jones, Jung-Min Lee, Stéphanie Lheureux, Joyce F Liu,[...]. J Clin Oncol 2020
96
7

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
Eileen M O'Reilly, Jonathan W Lee, Mark Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A Lowery, Joanne F Chou, Vaibhav Sahai,[...]. J Clin Oncol 2020
167
7

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.
Sophia X Pfister, Enni Markkanen, Yanyan Jiang, Sovan Sarkar, Mick Woodcock, Giulia Orlando, Ioanna Mavrommati, Chen-Chun Pai, Lykourgos-Panagiotis Zalmas, Neele Drobnitzky,[...]. Cancer Cell 2015
195
7

Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
Amirali B Bukhari, Cody W Lewis, Joanna J Pearce, Deandra Luong, Gordon K Chan, Armin M Gamper. J Clin Invest 2019
69
10

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
46
15

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, Michał Mikuła, Jerzy Ostrowski, Agnieszka Śliwińska, Aneta Rogalska. Int J Mol Sci 2020
13
53

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
380
6

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Young Eun Choi, Khyati Meghani, Marie-Eve Brault, Lucas Leclerc, Yizhou J He, Tovah A Day, Kevin M Elias, Ronny Drapkin, David M Weinstock, Fanny Dao,[...]. Cell Rep 2016
97
6

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Amy Dréan, Chris T Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac Garcia-Murillas, Helen N Pemberton, Jessica Frankum, Rumana Rafiq,[...]. Mol Cancer Ther 2017
49
12

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018
68
8

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
313
6

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
395
6

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
6

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Minli Wang, Weizhong Wu, Wenqi Wu, Bustanur Rosidi, Lihua Zhang, Huichen Wang, George Iliakis. Nucleic Acids Res 2006
559
6

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Nidal E Muvarak, Khadiza Chowdhury, Limin Xia, Carine Robert, Eun Yong Choi, Yi Cai, Marina Bellani, Ying Zou, Zeba N Singh, Vu H Duong,[...]. Cancer Cell 2016
115
6

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
348
6

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
462
6

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli,[...]. Ann Oncol 2018
128
6

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Alanna R Kaplan, Susan E Gueble, Yanfeng Liu, Sebastian Oeck, Hoon Kim, Zhong Yun, Peter M Glazer. Sci Transl Med 2019
76
7

Targeting the ATR-CHK1 Axis in Cancer Therapy.
Stuart Rundle, Alice Bradbury, Yvette Drew, Nicola J Curtin. Cancers (Basel) 2017
136
6

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie-Ming Shih,[...]. Cancer Discov 2015
278
6

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Lukas Perkhofer, Anna Schmitt, Maria Carolina Romero Carrasco, Michaela Ihle, Stephanie Hampp, Dietrich Alexander Ruess, Elisabeth Hessmann, Ronan Russell, André Lechel, Ninel Azoitei,[...]. Cancer Res 2017
71
8

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim,[...]. Mol Cancer Ther 2017
78
7

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
Luis I Toledo, Matilde Murga, Rafal Zur, Rebeca Soria, Antonio Rodriguez, Sonia Martinez, Julen Oyarzabal, Joaquin Pastor, James R Bischoff, Oscar Fernandez-Capetillo. Nat Struct Mol Biol 2011
353
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.